<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111420</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-0085</org_study_id>
    <nct_id>NCT03111420</nct_id>
  </id_info>
  <brief_title>Study of AggreGuide A-100 (ADP) Assay</brief_title>
  <official_title>Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aggredyne, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aggredyne, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet
      dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study subjects will have A-100 ADP measurements performed at baseline and after initiation of
      P2Y12 inhibitor antiplatelet therapy, following loading and maintenance doses.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Platelet function test results are not provided to the participant, care provider, or investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Platelet Activity Index (PAI)</measure>
    <time_frame>Baseline, day 1, day 7</time_frame>
    <description>Platelet reactivity measurement using A-100 ADP assay</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Risk Factor, Cardiovascular</condition>
  <condition>Platelet Dysfunction Due to Drugs</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
Loading dose day 1. Maintenance dose over subsequent 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
Loading dose day 1. Maintenance dose over subsequent 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
Loading dose day 1. Maintenance dose over subsequent 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2Y12 inhibitor</intervention_name>
    <description>Administration of P2Y12 inhibitor antiplatelet therapy</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>clopidogrel</other_name>
    <other_name>prasugrel</other_name>
    <other_name>ticagrelor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Platelet function test</intervention_name>
    <description>Blood is drawn for testing of platelet aggregation activity</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>AggreGuide A-100 ADP assay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a history of cardiovascular disease OR

          -  Subject has 2 or more cardiac risk factors:

               -  Smoking

               -  Hypertension

               -  Hyperlipidemia

               -  Family History of Heart Disease

               -  Post-menopausal female

               -  Diabetes

               -  Obesity (BMI &gt; 30)

               -  Sedentary lifestyle

        Exclusion Criteria:

        Taken nonsteroidal anti-inflammatory drugs (NSAIDs) drugs, anti-platelet drugs or
        anticoagulant drugs within the past seven (7) days, over age 75, under 60 kg body weight,
        in the last trimester of pregnancy or breastfeeding, with a diagnosed history of: stroke or
        transient ischemic attacks, or other thromboembolic disease, anemia, thrombocytopenia,
        uncontrolled hypertension,platelet disorders,hemophilia or other bleeding disorder,
        gastrointestinal disease, severe renal disease, expect to engage in contact sports,
        scheduled for elective surgery, have a medical history as determined by the Investigator
        that would pose safety concerns, or possess contraindications for any of the study
        medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Speros</last_name>
    <role>Study Director</role>
    <affiliation>Aggredyne, Inc.</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Platelet Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

